Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer

Inclusion Criteria:

* 1.Age: from 18 to 70 years old, female.
* 2.Has histologically or cytologically confirmed unilateral primary invasive breast cancer with a clinical stage of T2-4NanyM0.
* 3.Immunohistochemical detection of ER+, PR+, HER-2 negative (if HER2 expression is 2+ patients need to be confirmed by in situ hybridization to detect no HER-2 gene amplification) and Ki-67 expression \>20% of patients;
* 4.At least one measurable objective lesion according to RECIST 1.1 criteria.
* 5.ECOG performance status of 0-1.
* 6.Bone marrow function: Neutrophils ≥ 1.5×109/L, platelets ≥ 100×109/L, and hemoglobin ≥ 90 g/L.
* 7.Liver and renal function: Serum creatinine ≤ 1.5 times the upper limit of normal. AST and ALT ≤ 2.5 times the upper limit of normal Total bilirubin ≤ 1.5 times the upper limit of normal, or ≤ 2.5 times the upper limit of normal in patients with Gilbert's syndrome.
* 8.Has good compliance with the planned treatment, understand the study process and sign written informed consent.

Exclusion Criteria:

* 1.Any prior cytotoxic chemotherapy, endocrine therapy, biological therapy, or radiation therapy.
* 2.Patients with grade II or higher heart disease scored by the New York Heart Association (NYHA).
* 3.Severe systemic infection, or with other serious diseases.
* 4.Patients with known hypersensitivity or intolerance to chemotherapeutic agents or their excipients.
* 5.Other malignancies have occurred in the past 5 years, except for cured cervical carcinoma in situ, non-melanoma skin carcinoma.
* 6.Pregnant or lactating, and who refuse to take appropriate contraception during the course of this trial.
* 7.Have participated in other study studies within 30 days prior to the first dose of study drug.
* 8.Patients who, in the opinion of the Investigator, are not suitable for participation in the study.